Alexander, T., & Lorenz, H. (2015). The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Annals of the rheumatic diseases, 74(7), . https://doi.org/10.1136/annrheumdis-2014-206016
Chicago-Zitierstil (17. Ausg.)Alexander, Tobias, und Hanns-Martin Lorenz. "The Proteasome Inhibitior Bortezomib Depletes Plasma Cells and Ameliorates Clinical Manifestations of Refractory Systemic Lupus Erythematosus." Annals of the Rheumatic Diseases 74, no. 7 (2015). https://doi.org/10.1136/annrheumdis-2014-206016.
MLA-Zitierstil (9. Ausg.)Alexander, Tobias, und Hanns-Martin Lorenz. "The Proteasome Inhibitior Bortezomib Depletes Plasma Cells and Ameliorates Clinical Manifestations of Refractory Systemic Lupus Erythematosus." Annals of the Rheumatic Diseases, vol. 74, no. 7, 2015, https://doi.org/10.1136/annrheumdis-2014-206016.